Featured Research

from universities, journals, and other organizations

Well-Tolerated Tolterodine Cuts Incontinence Episodes In Half In Overactive Bladder Patients

Date:
August 26, 1999
Source:
University Of Toronto
Summary:
Research presented today at the International Continence Society (ICS) 29th Annual Meeting and the International Urogynecologic Association (IUGA) 24th Annual Meeting shows that tolterodine (Detrolä) not only reduces incontinence episodes (or wetting accidents) by 50 percent in overactive bladder patients, but also is well-tolerated for long-term treatment.

Research presented today at the International Continence Society (ICS) 29th Annual Meeting and the International Urogynecologic Association (IUGA) 24th Annual Meeting shows that tolterodine (Detrolä) not only reduces incontinence episodes (or wetting accidents) by 50 percent in overactive bladder patients, but also is well-tolerated for long-term treatment.

Dr. Harold Drutz, University of Toronto, Canada, Dr. Paul Abrams, Bristol Urological Institute, UK, et. al. found that patients treated with tolterodine achieved significant improvements in incontinence episodes, frequency of micturition (urination) and amount of urine voided per micturition.

"In the past, therapy for overactive bladder has been limited to drugs with poor tolerability, leading to low compliance or early discontinuation of treatment," says Drutz, Professor and Head, Section of Urogynecology, Department of Ob/Gyn, University of Toronto and Head, Urogynecology, Mount Sinai Hospital. "This study confirms that tolterodine is very effective in reducing incontinence episodes, and offers improved tolerability for long-term treatment of overactive bladder. As a result, tolterodine increases patient satisfaction and compliance."

Overactive bladder is a serious, chronic disease that effects 50 million people worldwide of all ages. Despite its prevalence, 80 percent of those suffering with overactive bladder are not under a physician's care. Many sufferers fail to seek medical help because they mistakenly believe, or are even told by physicians, that bladder control problems are an inevitable part of aging and nothing can be done to help. Sufferers are also too embarrassed to talk about their problem with a physician.

Researchers studied 2,220 patients who were enrolled in 2-, 4-, or 12-week double-blind, placebo-controlled studies with tolterodine or placebo. Of this group, seventy-five percent of patients (a total of 1,669) elected to continue on long-term open-label treatment with tolterodine 2 mg BID. Incontinence episodes were significantly reduced (p<0.0001) from 3.2 at baseline to 1.6 after 12 months of treatment with tolterodine. Of interest, thirty-five percent of the 1669 patients who participated in the study experienced poor efficacy on other treatments.

Compared to other drugs used to treat overactive bladder, tolterodine is selective for bladder tissue over salivary gland tissue in the body, thus reducing the incidence of dry mouth, the most common side effect. The severity of dry mouth reported during the study was low and not troublesome to patients. Only four percent discontinued the study because of treatment-associated dry mouth. A total of 66 percent of patients (a total of 1106) completed 12 months of treatment with tolterodine.

Overactive bladder is marked by symptoms of frequency, urgency, with or without urge incontinence. Frequency means urinating more than eight times within a 24-hour period, while urgency is a sudden, overwhelming urge to urinate. Urge incontinence is the sudden and involuntary loss of urine, which may often follow the sense of urgency. Only forty percent of people with overactive bladder experience urge incontinence. This study was sponsored by Pharmacia & Upjohn.


Story Source:

The above story is based on materials provided by University Of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University Of Toronto. "Well-Tolerated Tolterodine Cuts Incontinence Episodes In Half In Overactive Bladder Patients." ScienceDaily. ScienceDaily, 26 August 1999. <www.sciencedaily.com/releases/1999/08/990825163813.htm>.
University Of Toronto. (1999, August 26). Well-Tolerated Tolterodine Cuts Incontinence Episodes In Half In Overactive Bladder Patients. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/1999/08/990825163813.htm
University Of Toronto. "Well-Tolerated Tolterodine Cuts Incontinence Episodes In Half In Overactive Bladder Patients." ScienceDaily. www.sciencedaily.com/releases/1999/08/990825163813.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) — Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins